|
業務類別
|
-- |
|
業務概覽
|
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are usedto control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan. |
| 公司地址
| 1-6-1 Marunouchi, Chiyoda-ku, Tokyo, JPN, 100-0005 |
| 電話號碼
| +81 352208950 |
| 傳真號碼
| +81 352208951 |
| 公司網頁
| http://www.seikagaku.co.jp |
| 員工數量
| 1260 |
| Mr. Ken Mizutani |
Chief Executive Officer, Director and President |
-- |
18/06/2026 |
| Mr. Toshiyuki Okada |
Director, Senior Managing Executive Officer and Head of Reliability Assurance Division |
-- |
18/06/2026 |
| Mr. Yosuke Funakoshi |
Director and Executive Vice President, Research and Development |
-- |
18/06/2026 |
|
|
| Mr. Masaji Santo |
Independent Director |
18/06/2026 |
| Mr. Yasuyuki Sugiura |
Independent Director |
18/06/2026 |
| Mr. Ken Mizutani |
Chief Executive Officer, Director and President |
18/06/2026 |
| Mr. Toshiyuki Okada |
Director, Senior Managing Executive Officer and Head of Reliability Assurance Division |
18/06/2026 |
| Mr. Yosuke Funakoshi |
Director and Executive Vice President, Research and Development |
18/06/2026 |
| Ms. Mio Minaki |
Independent Director |
18/06/2026 |
| Mr. Ryoji Tomokiyo |
Director |
18/06/2026 |
|
|
|
|
